View Financial HealthBiogen 配当と自社株買い配当金 基準チェック /06Biogen配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBiogen Inc. to Report Q1, 2026 Results on Apr 29, 2026Apr 07Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS) from The Morningside Group Limited and others for $5.6 billion.Apr 02Biogen Inc. Announces Approval Of High Dose Regimen Of Spinraza For Spinal Muscular AtrophyMar 30Biogen Inc. Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus ErythematosusMar 29Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21Block & Leviton LLP Announces United States District Court for the District of Massachusetts Certifies Class Action on Behalf of Purchasers of Biogen, Inc. SecuritiesMar 19+ 1 more updateBiogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026Mar 14Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial ProgramMar 12Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet SyndromeMar 06+ 1 more updateBiogen Inc., Annual General Meeting, Jun 09, 2026Feb 12+ 1 more updateNature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular AtrophyFeb 04Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease with No Targeted Treatment OptionsJan 28Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyJan 13Biogen Inc. to Report Q4, 2025 Results on Feb 06, 2026Jan 09Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeDec 05Eisai Co., Ltd. and Biogen Inc. Present New DataDec 04Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025Dec 03Biogen to Highlight New Lecanemab Data and Scientific Advances At the 18Th Clinical Trials on Alzheimer's Disease ConferenceNov 21Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet SyndromeNov 17Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025Oct 22Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeOct 10Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07Biogen Inc. to Report Q3, 2025 Results on Oct 30, 2025Sep 27Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Alcyone Therapeutics, Inc. for $85 million.Sep 19+ 1 more updateC4 Therapeutics Highlights Recent Achievement in Biogen CollaborationSep 04Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet SyndromeSep 03Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy CongressAug 25+ 1 more updateStoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet SyndromeAug 12Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025Jul 30+ 1 more updateBiogen Inc. Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum DepressionJul 25Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJul 10Biogen Inc. to Report Q2, 2025 Results on Jul 31, 2025Jul 02Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyJul 01Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMAJun 28Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 ResultsJun 25Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich AtaxiaJun 18UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus ErythematosusJun 12Biogen Inc., Annual General Meeting, Jun 17, 2025Apr 29Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16BioPharma Credit PLC Enters into Settlement Agreement with BiogenApr 03+ 1 more updateEisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28Biogen Inc. Provides Earnings Guidance for the Full Year 2025Feb 13Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External InnovationJan 10Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNov 28Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZNov 19Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical AffairsOct 30Biogen Inc. Announces Chief Financial Officer ChangesOct 28+ 1 more updateBiogen Inc. to Report Q3, 2024 Results on Oct 30, 2024Oct 04Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, RespectivelySep 12Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential TremorJul 24Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.Jul 03Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in ChinaJun 28Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024Jun 26Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.May 23+ 1 more updateBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 18Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16Biogen Inc., Annual General Meeting, Jun 20, 2024Apr 28Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRAApr 27Biogen Inc. Provides Earnings Guidance for the Full Year of 2024Apr 24Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024Apr 11Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term GrowthJan 31Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024Jan 13CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's AtaxiaDec 16Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIVDec 15Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023Nov 10Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024Nov 07Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's DiseaseOct 27Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023Oct 12FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®Oct 01Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).Sep 27Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in JapanSep 25Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's BiosimilarsSep 18Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023Sep 07Sanofi Reportedly Second Bidder for ReataAug 17Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.Jul 29Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023Jul 26Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023Jul 22Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023Jul 12Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s DiseaseJul 07Biogen Announces Board ChangesJun 28Biogen Inc., Annual General Meeting, Jun 26, 2023Jun 15Biogen Announces Changes to Its Board of DirectorsJun 13Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory CommitteeJun 12決済の安定と成長配当データの取得安定した配当: BIIBの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BIIBの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Biogen 配当利回り対市場BIIB 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BIIB)n/a市場下位25% (AR)0%市場トップ25% (AR)0%業界平均 (Biotechs)0%アナリスト予想 (BIIB) (最長3年)0%注目すべき配当: BIIBは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BIIBは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BIIBの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BIIBが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YAR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 05:37終値2026/05/04 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biogen Inc. 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。58 アナリスト機関David ToungArgus Research CompanyBrian SkorneyBairdEmily FieldBarclays55 その他のアナリストを表示
Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS) from The Morningside Group Limited and others for $5.6 billion.Apr 02
Biogen Inc. Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus ErythematosusMar 29
Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21
Block & Leviton LLP Announces United States District Court for the District of Massachusetts Certifies Class Action on Behalf of Purchasers of Biogen, Inc. SecuritiesMar 19+ 1 more update
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026Mar 14
Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet SyndromeMar 06+ 1 more update
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular AtrophyFeb 04
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease with No Targeted Treatment OptionsJan 28
Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyJan 13
Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeDec 05
Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025Dec 03
Biogen to Highlight New Lecanemab Data and Scientific Advances At the 18Th Clinical Trials on Alzheimer's Disease ConferenceNov 21
Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet SyndromeNov 17
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025Oct 22
Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeOct 10
Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07
Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24
Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Alcyone Therapeutics, Inc. for $85 million.Sep 19+ 1 more update
Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet SyndromeSep 03
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy CongressAug 25+ 1 more update
Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet SyndromeAug 12
Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025Jul 30+ 1 more update
Biogen Inc. Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum DepressionJul 25
Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJul 10
Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyJul 01
Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMAJun 28
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 ResultsJun 25
Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich AtaxiaJun 18
UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus ErythematosusJun 12
Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16
Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28
Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28
Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14
Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External InnovationJan 10
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05
Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNov 28
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZNov 19
Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15
Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01
Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, RespectivelySep 12
Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential TremorJul 24
Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.Jul 03
Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.May 23+ 1 more update
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 18
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16
Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRAApr 27
Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term GrowthJan 31
CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's AtaxiaDec 16
Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIVDec 15
Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024Nov 07
Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's DiseaseOct 27
Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in JapanSep 25
Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023Sep 07
Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.Jul 29
Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023Jul 22
Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s DiseaseJul 07
Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory CommitteeJun 12